Nuveen LLC Invests $465,000 in Tyra Biosciences, Inc. $TYRA

Key Points

• Nuveen LLC has acquired a new stake in Tyra Biosciences, Inc., purchasing nearly 50,000 shares valued at approximately $465,000, which represents about 0.09% of the company's stock.
• Several institutional investors have significantly increased their holdings in Tyra Biosciences during the fourth quarter, with Janus Henderson Group PLC boosting its stake by 63.6% and Orbimed Advisors LLC by 91.3%.
• Tyra Biosciences recently reported an EPS of ($0.47) for the quarter, exceeding analysts’ expectations, and has a consensus price target of $31.43 based on ratings from multiple research analysts.

Nuveen LLC purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 49,998 shares of the company's stock, valued at approximately $465,000. Nuveen LLC owned approximately 0.09% of Tyra Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of TYRA. US Bancorp DE lifted its stake in shares of Tyra Biosciences by 50.5% in the first quarter. US Bancorp DE now owns 5,435 shares of the company's stock worth $51,000 after buying an additional 1,823 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Tyra Biosciences in the fourth quarter worth about $60,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Tyra Biosciences in the first quarter worth about $84,000. Exchange Traded Concepts LLC lifted its stake in shares of Tyra Biosciences by 42.7% in the first quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after buying an additional 3,550 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after buying an additional 3,236 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, August 22nd. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 price objective for the company. Finally, Raymond James Financial started coverage on shares of Tyra Biosciences in a report on Tuesday. They issued a "strong-buy" rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $31.43.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 30,000 shares of the stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $10.31, for a total transaction of $309,300.00. Following the completion of the transaction, the director owned 59,623 shares of the company's stock, valued at $614,713.13. This trade represents a 33.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 61,392 shares of company stock worth $628,358 over the last ninety days. Company insiders own 15.20% of the company's stock.

Tyra Biosciences Stock Up 4.2%

TYRA stock traded up $0.51 during mid-day trading on Friday, hitting $12.65. 230,201 shares of the company were exchanged, compared to its average volume of 219,947. The firm has a market capitalization of $674.25 million, a P/E ratio of -7.11 and a beta of 1.10. The business has a fifty day simple moving average of $10.96 and a 200-day simple moving average of $10.28. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. Research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.